How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,547 results for

fluoroquinolones

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Re: Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients with Elevated Serum Prostate-Specific Antigen is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. (Abstract)

Re: Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients with Elevated Serum Prostate-Specific Antigen is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. 29539905 2018 12 21 2018 12 21 1527-3792 197 5 2017 05 The Journal of urology J. Urol. Re: Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients with Elevated Serum Prostate-Specific Antigen is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. 1276 S0022-5347(17)30279-3 10.1016/j.juro (...) .2017.02.058 Schaeffer Edward M EM eng Journal Article Comment 2017 02 21 United States J Urol 0376374 0022-5347 0 Anti-Bacterial Agents 0 Anti-Infective Agents 0 Fluoroquinolones EC 3.4.21.77 Prostate-Specific Antigen AIM IM Urology. 2016 Apr;90:32-7 26802800 Anti-Bacterial Agents Anti-Infective Agents Fluoroquinolones Humans Male Prostate-Specific Antigen 2018 3 16 6 0 2018 3 16 6 0 2018 12 24 6 0 ppublish 29539905 S0022-5347(17)30279-3 10.1016/j.juro.2017.02.058

2018 The Journal of urology Controlled trial quality: uncertain

122. Effect of fluoroquinolone resistance mutation Thr-82→Ile on Clostridioides difficile fitness. (Full text)

Effect of fluoroquinolone resistance mutation Thr-82→Ile on Clostridioides difficile fitness. Fluoroquinolone resistance is common among epidemic Clostridioides difficile PCR ribotype (RT) 027 and may have contributed to outbreaks of C. difficile infection (CDI). We investigated the impact of fluoroquinolone mutations on the bacterial fitness (BF) of C. difficile RT027 isolates.The BF of seven RT027 mutants with reduced susceptibility to moxifloxacin (moxifloxacin MIC 4-32 mg/L) was compared (...) prevalent fluoroquinolone resistance mutations may have contributed to the success of RT027. Furthermore, a demonstrable in vitro advantage over fluoroquinolone-susceptible parent strains in CC may contribute to the maintenance of RT027, even in the absence of fluoroquinolone selection pressure.© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

2018 Journal of Antimicrobial Chemotherapy PubMed abstract

123. A Randomized Trial to Assess the Effect of Fluoroquinolone Metaphylaxis on the Fecal Prevalence and Quinolone Susceptibilities of Salmonella and Campylobacter in Feedlot Cattle. (Abstract)

A Randomized Trial to Assess the Effect of Fluoroquinolone Metaphylaxis on the Fecal Prevalence and Quinolone Susceptibilities of Salmonella and Campylobacter in Feedlot Cattle. The study objective was to determine effects of fluoroquinolone metaphylaxis on fecal prevalence of Salmonella and Campylobacter and fecal prevalence of quinolone-resistant Salmonella and Campylobacter in feedlot cattle. On Day 0, cattle (n = 288) at risk for bovine respiratory disease (BRD) were randomly assigned (...) to either a nontreated control pen (12 pens) or a fluoroquinolone-treated (enrofloxacin; Baytril® 100) pen (12 pens). Rectal fecal samples were collected from cattle on days 0, 7, 14, 21, and 28. Feces were cultured for Salmonella enterica and Campylobacter spp. using enrichment and selective isolation methods, and confirmed by serology and PCR. Susceptibilities to nalidixic acid and ciprofloxacin were determined using microbroth dilution methods. Data analyses were performed using linear mixed models

2018 Foodborne pathogens and disease Controlled trial quality: uncertain

124. Can some benefit the use of a fluoroquinolone agent in patients with periodontitis? A systematic review and meta-analysis

Can some benefit the use of a fluoroquinolone agent in patients with periodontitis? A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

125. The pharmacokinetic profiles of fluoroquinolones in the treatment of tuberculosis in adults: protocol for a systematic review and meta-analysis

The pharmacokinetic profiles of fluoroquinolones in the treatment of tuberculosis in adults: protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

126. Systemic fluoroquinolone use and emerging serious adverse drug reactions: an umbrella review of evidence from meta-analysis.

Systemic fluoroquinolone use and emerging serious adverse drug reactions: an umbrella review of evidence from meta-analysis. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

127. E. coli resistance in community-acquired uncomplicated urinary tract infection in women - the evolving case of fluoroquinolones, and implications for patient management: a systematic review

E. coli resistance in community-acquired uncomplicated urinary tract infection in women - the evolving case of fluoroquinolones, and implications for patient management: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2020 PROSPERO

128. In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default? (Abstract)

In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default? Fluoroquinolone use might be associated with serious side effects. Urologists should always consider these potential risks associated with fluoroquinolones and participate in a shared-decision making process with each patient. It is critical to strictly follow guidelines when prescribing fluoroquinolones.Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2018 European urology

129. Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis. (Abstract)

Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis. The goal of this study was to investigate whether ceftriaxone combination therapy is associated with better clinical outcomes than respiratory fluoroquinolone monotherapy for adults with community-acquired pneumonia (CAP). We conducted a meta-analysis of published studies.Using the PubMed, EMBASE, and Cochrane Library databases, we performed a literature search (...) of available randomized controlled trials (RCTs) published as original articles before September 2017.Nine RCTs, involving 1520 patients, were included in the meta-analysis. The pooled relative risks (RRs) for the efficacy of ceftriaxone combination therapy versus respiratory fluoroquinolones monotherapy were 0.96 (95% CI: 0.92-1.01), based on clinically evaluable populations, and 0.93 (95% CI: 0.88-0.99) based on intention-to-treat (ITT) populations. No statistically significant differences were observed

2018 American Journal of Emergency Medicine

130. High prevalence of fluoroquinolone resistance amongst commensal flora of antibiotic naïve neonates: a study from India. (Full text)

High prevalence of fluoroquinolone resistance amongst commensal flora of antibiotic naïve neonates: a study from India. The emergence of resistance amongst commensal flora is a serious threat to the community. However, there is paucity of data regarding antibiotic resistance in commensals in the absence of antibiotic pressure.Altogether, 100 vaginally delivered antibiotic naïve exclusively breastfed neonates were selected. Stool samples collected on day (D)1, D21 and D60 of birth were cultured (...) were isolated from 100 neonates. On D1, 58 % of neonates were colonized with at least one Enterobacteriaceae predominantly E. coli. Overall resistance to NA was 60 % but ciprofloxacin resistance increased significantly from 15 % (14/96) on D1 to 38 % (50/132) on D60 (P-value <0.001). The predominant mechanism of fluoroquinolone resistance was mutation in gyrA (n=49) with or without PMQR. PMQR carrying isolates increased more than fivefold from D1 to D60.A high level of fluoroquinolone resistance

2018 Journal of Medical Microbiology PubMed abstract

131. Overexpression of Stenotrophomonas maltophilia major facilitator superfamily protein MfsA increases resistance to fluoroquinolone antibiotics. (Full text)

Overexpression of Stenotrophomonas maltophilia major facilitator superfamily protein MfsA increases resistance to fluoroquinolone antibiotics. Stenotrophomonas maltophilia is an opportunistic human pathogen causing nosocomial infections worldwide. S. maltophilia infection is of particular concern due to its inherent resistance to currently used antibiotics. Proton motive force-driven transporters of the major facilitator superfamily frequently contribute to the efflux of substances, including (...) antibiotics, across cell membranes.An mfsA expression plasmid (pMfsA) was constructed and transferred into bacterial strains by electroporation. The antibiotic susceptibility levels of S. maltophilia strains were determined using standard methods.S. maltophilia MfsA is an efflux pump associated with paraquat resistance. We show here that plasmid-mediated overexpression of mfsA in WT S. maltophilia K279a increased resistance not only to paraquat but also to second-generation fluoroquinolone antibiotics

2018 Journal of Antimicrobial Chemotherapy PubMed abstract

132. Pediatric fluoroquinolone prescription in South Korea before and after a regulatory intervention: A nationwide study, 2007-2015. (Full text)

Pediatric fluoroquinolone prescription in South Korea before and after a regulatory intervention: A nationwide study, 2007-2015. To investigate the impact of national implementation of age restriction on fluoroquinolone prescription in children and adolescents.Data collected from the database of Health Insurance Review and Assessment Service in South Korea, a national health insurance system to analyze fluoroquinolone prescribing practice in children and adolescents younger than 18 years (...) , between 2007 and 2015. The age restriction was implemented in December 2009. The annual prescription rate of FQ per 100,000 person-years was calculated and an autoregressive model was used to predict the prescription pattern if an intervention had not occurred.A total of 505,859 children received systemic fluoroquinolone during the study period-297,054 ciprofloxacin, and 208,805 levofloxacin. After implementation of the drug utilization review program, the annual prescription rate for ciprofloxacin

2017 PLoS ONE PubMed abstract

133. Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia. (Full text)

Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia. Resistance in the sexually transmitted bacterium Mycoplasma genitalium to all recommended therapeutic antimicrobials have rapidly emerged. However, to date, internationally reported resistance surveillance data for M. genitalium strains circulating in Eastern Europe are entirely lacking. The aim of this study was to estimate the prevalence of macrolide (...) and fluoroquinolone resistance-associated mutations in M. genitalium in four cities in Russia and one in Estonia, 2013-2016.Consecutive urogenital samples found positive for M. genitalium during diagnostic testing were retrospectively analyzed for resistance-associated mutations in the 23S rRNA and parC genes using pyrosequencing and conventional Sanger sequencing, respectively.In total, 867 M. genitalium positive samples from 2013-2016 were analyzed. Macrolide resistance-associated mutations were detected in 4.6

2017 PLoS ONE PubMed abstract

134. In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains. (Full text)

In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains. Mycoplasma genitalium is estimated to be the second most common cause of bacterial sexually transmitted infection in Europe. It is of increasing public health concern due to the rapid development of resistance to different antimicrobial classes, including the preferred first- and second-line treatments azithromycin and moxifloxacin. Thus

2018 Journal of Antimicrobial Chemotherapy PubMed abstract

135. Clinical review of delafloxacin: a novel anionic fluoroquinolone. (Full text)

Clinical review of delafloxacin: a novel anionic fluoroquinolone. Delafloxacin is a novel anionic fluoroquinolone (FQ) approved for treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by a number of Gram-positive and Gram-negative organisms including MRSA and Pseudomonas aeruginosa. The unique chemical structure of delafloxacin renders it a weak acid and results in increased potency in acidic environments. In Phase III studies, delafloxacin had similar outcomes

2018 Journal of Antimicrobial Chemotherapy PubMed abstract

136. Reduced Risk of Sepsis after Prostate Biopsy Using a Cephalosporin/Fluoroquinolone Antibiotic Regimen and Isopropyl Alcohol Needle Washing. (Abstract)

Reduced Risk of Sepsis after Prostate Biopsy Using a Cephalosporin/Fluoroquinolone Antibiotic Regimen and Isopropyl Alcohol Needle Washing. To compare 3 prophylactic regimens to assess their impact on postbiopsy sepsis incidence.Data were reviewed for 829 consecutive patients who underwent prostate biopsy in a community practice setting between January 2013 and October 2017. Group 1 patients received ciprofloxacin 500 mg two times a day orally for 4 days starting the day prior to biopsy

2018 Urology

137. Systemic fluoroquinolone prescriptions for hospitalized children in Belgium, results of a multicenter retrospective drug utilization study. (Full text)

Systemic fluoroquinolone prescriptions for hospitalized children in Belgium, results of a multicenter retrospective drug utilization study. Fluoroquinolones (FQ) are increasingly prescribed for children, despite being labeled for only a limited number of labeled pediatric indications. In this multicenter retrospective drug utilization study, we analyzed indications for systemic FQ prescriptions in hospitalized children and the appropriateness of the prescribed dose.Using data obtained from

2018 BMC Infectious Diseases PubMed abstract

138. High admission prevalence of fluoroquinolone resistance in third-generation cephalosporin-resistant Enterobacteriaceae in German university hospitals. (Full text)

High admission prevalence of fluoroquinolone resistance in third-generation cephalosporin-resistant Enterobacteriaceae in German university hospitals. Fluoroquinolone resistance (FQR) in third-generation cephalosporin-resistant Enterobacteriaceae (3GCRE) presents serious limitations to antibiotic therapy. The aim of this study was to investigate whether the FQR proportion among 3GCRE differs between community-acquired (CA) and hospital-acquired (HA) isolates.In a prospective observational study

2018 Journal of Antimicrobial Chemotherapy PubMed abstract

139. Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits. (Full text)

Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits. The Food and Drug Administration warned against fluoroquinolone use for conditions with effective alternative agents. An estimated 5.1% of adult ambulatory fluoroquinolone prescriptions were for conditions that did not require antibiotics, and 19.9% were for conditions where fluoroquinolones are not recommended first-line therapy. Unnecessary fluoroquinolone use should be reduced.

2018 Clinical Infectious Diseases PubMed abstract

140. Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays? (Full text)

Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays? 29549060 2018 11 05 2018 11 05 1469-0691 24 7 2018 Jul Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases Clin. Microbiol. Infect. Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays? 678-679 S1198-743X(18)30208-8 10.1016/j.cmi.2018.02.031 Mikulska M M Division of Infectious Diseases, University of Genoa (DISSAL (...) ) and Ospedale Policlinico San Martino, Genoa, Italy. Electronic address: m.mikulska@unige.it. Cordonnier C C Department of Haematology, Henri Mondor Teaching Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris-Est-Créteil, Créteil, France. eng Letter 2018 03 13 England Clin Microbiol Infect 9516420 1198-743X 0 Fluoroquinolones IM Antibiotic Prophylaxis Disease Management Drug Resistance, Microbial Fluoroquinolones therapeutic use Hematologic Neoplasms complications therapy Humans Neutropenia

2018 Clinical Microbiology and Infection PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>